Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Alexion's Rare Bone Drug Strensiq 'Not Value For Money'

This article was originally published in Scrip

Executive Summary

NICE, the HTA body for England and Wales, has issued draft guidance that does not recommend Alexion's rare bone disease treatment Strensiq (asfotase alfa) for pediatric-onset hypophosphatasia.

Advertisement
Advertisement
UsernamePublicRestriction

Register